SCHEMBL13613506

SCHEMBL13613506

O=C1c2ccccc2CN1Cc1ccc(Cl)cc1Cl

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
GAA P10253 1/20 0.55
LMNA P02545 3/20 0.52
MAPT P10636 3/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
HTT P42858 1/20 0.52
P2RX7 Q99572 4/20 0.50
ALDH1A1 P00352 2/20 0.50
POLB P06746 1/20 0.50
DRD2 P14416 2/20 0.47
DRD3 P35462 2/20 0.47
DRD5 P21918 1/20 0.47
SIGMAR1 Q99720 1/20 0.47
TSHR P16473 2/20 0.46
MAPK1 P28482 1/20 0.46
KCNH2 Q12809 1/20 0.46
CASP6 P55212 1/20 0.46
KDM4E B2RXH2 1/20 0.46
ALOX15 P16050 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2026716 0.85 DRD2 (0.55) MEN1KMT2ALMNAMAPTSMN1; SMN2
SCHEMBL2026017 0.83 DRD2 (0.43) MEN1KMT2AGAALMNAMAPT
SCHEMBL2024397 0.81 KMT2A (0.60) MEN1KMT2AGAAMAPTPOLB
SCHEMBL31252762 0.81 KMT2A (0.60) MEN1KMT2AGAAMAPTPOLB
SCHEMBL23349230 0.80 KDM4E (0.57) MEN1KMT2ASMN1; SMN2ALDH1A1DRD2
SCHEMBL2029640 0.79 MEN1 (0.64) MEN1KMT2AGAAMAPTSMN1; SMN2
SCHEMBL155188 0.78 DRD2 (0.44) MEN1KMT2AP2RX7DRD2DRD3
SCHEMBL11081773 0.76 MAPT (0.58) MEN1KMT2AGAALMNAMAPT
SCHEMBL29630944 0.76 KMT2A (0.60) MEN1KMT2AMAPTSMN1; SMN2ALDH1A1
SCHEMBL1466305 0.76 KMT2A (0.60) MEN1KMT2AMAPTSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2009-11-05 US disclosed
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators GRM1, GRIN1, GRM3 MEN1 2588/4885KMT2A 3975/4885GAA 4626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.